Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2018 07:45 ET | Source: Fundamental Markets

Market Trends Toward New Normal in Golden Ocean Group, Redhill Biopharma, Galapagos NV, Crawford, Amphastar Pharmaceuticals, and 51job — Emerging Consolidated Expectations, Analyst Ratings

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders,...
November 07, 2016 01:21 ET | Source: Morphosys AG

MorphoSys AG berichtet Ergebnisse der ersten neun Monate 2016

Martinsried / Munich, Germany, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Finanzprognose 2016 bestätigt Telefonkonferenz und Webcast (auf Englisch) heute um 14:00 Uhr MEZ Die MorphoSys AG...
November 07, 2016 01:21 ET | Source: Morphosys AG

MorphoSys AG Reports Results for the First Nine Months of 2016

Martinsried / Munich, Germany, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Financial Guidance for 2016 Confirmed Conference call and webcast (in English) today at 2:00pm CET (1:00pm GMT/8:00am EST) ...
September 29, 2016 01:36 ET | Source: MorphoSys AG

MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis

Ongoing phase 1 study in healthy volunteers now advanced to investigate MOR106 in patients with atopic dermatitis Favorable safety results shown in healthy volunteers receiving single...
September 25, 2016 20:20 ET | Source: Galapagos NV

Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease

MECHELEN, Belgium, Sept. 25, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) reports that Dr Severine Vermeire, principal investigator of the FITZROY Phase 2 study with investigational...
April 28, 2016 16:13 ET | Source: Galapagos NV

Galapagos kick-starts 2016 with Q1 cash position of EU988 M

First quarter financial results: Group revenues €14.8 M Group net profit €35.9 M End of first quarter cash €987.6 M, including €9.3 M in...
April 07, 2016 01:33 ET | Source: MorphoSys AG

MorphoSys and Galapagos Initiate Phase 1 Study in Joint Antibody Program MOR106

MARTINSRIED / MUNICH, Germany, April 7, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and Galapagos NV (Euronext & NASDAQ: GLPG) announced today that...
April 03, 2016 16:29 ET | Source: Galapagos NV

Galapagos increases share capital through warrant exercises

MECHELEN, Belgium, April 3, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 131,695 new...
March 25, 2016 17:06 ET | Source: Galapagos NV

Publication of the annual report and invitation to the Annual and Extraordinary Shareholders' Meetings

Mechelen, Belgium, March 25, 2016 (GLOBE NEWSWIRE) -- Today Galapagos NV (Euronext & NASDAQ: GLPG) has published its Annual Report for the financial year 2015. The Annual Report for the...
January 19, 2016 17:02 ET | Source: Galapagos NV

Galapagos and Gilead complete closing of their global collaboration for filgotinib

MECHELEN, Belgium and FOSTER CITY, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) and Gilead Sciences, Inc. (NASDAQ:GILD) announced today the closing and entry...